doi:https://doi.org/

Journal: Evidence-based Cardiology. 2013;(1): 18‑20

Read: 2258 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

. Evidence-based Cardiology. 2013;(1):18‑20. (In Russ.)

Использование инфографики авторами научных работ

References:

van Giezen J.J., Tomlinson W., Berntsson P., et al. AZD6140 (ticagrelor) binds to the human P2Y12 receptor independently from ADP, but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556-1565.
Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
van Giezen J.J., Sidaway J., Glaves P., et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2011;17:164-172.
Burki N.K., Dale W.J., Lee L.Y. Intravenous adenosine and dyspnea in humans. J Appl Physiol 2005;98:180-185.
Lerman B.B., Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation 1991;83:1499-1509.
Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-1323.
Nylander S., Femia E., Scavone M., et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. Arterioscler Thromb Vasc Biol 2012;32:A213.
Mahaffey K.W., Puma J.A., Barbagelata N.A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-1720.
Ross A.M., Gibbons R.J., Stone G.W., et al; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.